Company Overview and News
A startup cancer therapy developer and supportive care provider jointly established by Emory University and the University of Queensland (UQ) has raised $16 million in Series A financing.
Prescient Therapeutics (ASX:PTX) has been granted a new patent in Europe providing platform technology protection for its lead clinical compound PTX-200 (triciribine phosphate).
Prescient Therapeutics (ASX:PTX) has been granted a trading halt by the ASX, pending results from the company’s Phase 1b Breast Cancer trial.
Prescient Therapeutics (ASX:PTX) has successfully completed the first cohort in its Phase 1b clinical trial of PTX-200 plus cytarabine for acute myeloid leukaemia (AML).
PTX-200 inhibits an important tumour survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukaemia. The trial is being conducted at the H. Lee Moffitt Cancer Center in Florida, U.S. The Phase 1b/2 trial combines PTX-200 with cisplatin (standard of care chemotherapy) in patients with recurrent or persistent platinum-resistant ovarian cancer.
Prescient Therapeutics Ltd (ASX:PTX) has been issued two notices of patent allowance for its cancer drug candidate PTX-200 by the U.S. Patent and Trademark Office (USPTO). The allowances are for “Effective treatment of tumors and cancer with triciribine and related compounds” and “Compositions including triciribines and taxanes and methods of use thereof”. PTX-200 inhibits an important tumor survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukaemia.
Prescient Therapeutics Ltd (ASX:PTX) is well positioned to move ahead with three clinical trials underway for its lead cancer drug candidate PTX-200, after raising $10.04 million in new capital. In May, Prescient raised $7 million from life-science focused Australian institutional investors by issuing shares at $0.09 each. The company raised a further $3.04 million from an entitlement offer to shareholders, which was completed earlier this month.
Prescient Therapeutics (ASX:PTX) formerly Virax Holdings is a clinical stage oncology company developing novel compounds that show great promise as potential new therapies to treat a range of cancers that have become resistant to front line chemotherapy.
Stock Research Report
Pernix Therapeutics is a specialty pharmaceutical company focused on improving patients' lives by identifying, developing and commercializing differentiated products that address unmet medical needs. Its strategy is to continue to create shareholder value by:
- growing sales of the existing products in its portfolio in various ways, including identifying new growth opportunities; and
- acquiring additional marketed specialty products or products close to regulatory approval to leverage its existing expertise and infrastructure.
Pernix Therapeutics target underserved segments, such as central nervous system (CNS) indications, including neurology, pain and psychiatry. The company promote its core branded products to physicians through its sales forces. The company market its generic products through its wholly owned subsidiaries, Macoven and Cypress.
Its branded products include Treximet, a medication indicated for the acute treatment of migraine attacks, with or without aura, ...
2017-12-11 - Wilton
2017-12-11 - Wilton
2017-12-03 - Wilton
2017-11-27 - Wilton